Interactions between osteosarcoma cell lines and dendritic cells immune function: An in vitro study

Cellular Immunology

Volumn 253, Issue 1-2, 2008, Pages 71-80

  Muraro, Michela ^a   Mereuta, Oana M ^a   Saglio, Francesco ^a   Carraro, Francesca ^a   Berger, Massimo ^a   Madon, Enrico ^a   Fagioli, Franca ^a  

^a REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

Author keywords

Cytokines; Dendritic cells; Maturation; Osteosarcoma; Tumor immunity

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; CYTOKINE; HLA DR ANTIGEN;

ARTICLE; CELL CULTURE; CELL INTERACTION; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOPHENOTYPING; IN VITRO STUDY; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIGENS, CD; ANTIGENS, CD14; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; BIOLOGICAL MARKERS; CELL LINE, TUMOR; COCULTURE TECHNIQUES; DENDRITIC CELLS; HUMANS; IMMUNITY; IMMUNOGLOBULINS; INDOMETHACIN; INTERLEUKIN-12; MEMBRANE GLYCOPROTEINS; OSTEOSARCOMA; PHENOTYPE;

EID: 51449095562     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.05.002     Document Type: Article

References (34)

1. Bacci G., Ferrari S., Mercuri M., Bertoni F., Picci P., Manfrini M., Gasbarrini A., Forni C., Cesari M., and Campanacci M. Predictive factors for local recurrence in osteosarcoma: 540 patients with extremity tumors followed for minimum 2.5 years after neoadjuvant chemotherapy. Acta Orthop. Scand. 69 (1998) 230-236
2. Bacci G., Ferrari S., Tienghi A., Bretoni F., Mercuri M., Longhi A., Fiorentini G., Forni C., Bacchini P., Rimondini S., De Giorgi U., and Picci P. A comparison of methods of loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur. J. Surg. Oncol. 27 (2001) 98-104
3. Ward W.G., Mikaelian K., Dorey F., Mirra J.M., Sassoon A., Holmes E.C., Eilber F.R., and Eckardt J. Pulmonary metastasis of stage II B extremity osteosarcoma and subsequent pulmonary metastases. J. Clin. Oncol. 12 (1994) 1849-1858
4. Fagioli F., Aglietta M., Tienghi A., Ferrari S., Brach del Prever A., Vassallo E., Palmero A., Biasin E., Bacci G., Picci P., and Madon E. High dose chemotherapy in the treatment of relapsed osteosarcoma: an Italian Sarcoma Group study. J. Clin. Oncol. 20 (2002) 2150-2156
5. Foss FM. Immunologic mechanisms of antitumor activity. Semin. Oncol. 29 (2002) 5-11
6. Lechmann M., Berchtold S., Hauber J., and Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 23 (2002) 273-275
7. O'Doherty U., Peng M., Gezelter S., Swiggard W.J., Betjes M., Bhardwaj N., and Steinman R.M. Human blood contains two subsets of dendritic cells one immunologically mature and the other immature. Immunology 82 (1994) 487-493
8. Olweus J., BitMansour A., Warnke R., Thompson P.A., Carballido J., Picker L.J., and Lund-Johansen F. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc. Natl. Acad. Sci. USA 94 (1997) 12551-12556
9. Reid S.D., Penna G., and Adorini L. The control of T cell responses by dendritic cell subsets. Curr. Opin. Immunol. 12 (2000) 114-121
10. Thomas R., and Lipsky PE. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. J. Immunol. 153 (1994) 4016-4028
11. Willmann K., and Dunne J.F. A flow cytometric immune function assay for human peripheral blood dendritic cells. J. Leukoc. Biol. 67 (2000) 536-544
12. Almeida J., Bueno C., Alguero M.C., Sanchez M.L., Canizo M.C., Fernandez M.E., Vaquero J.M., Laso F.J., Escribano L., San Miguel J.F., and Orfao A. Extensive characterization of the immunophenotype and pattern of cytokine production by distinct subpopulations of normal human peripheral blood MHC/lineage-cells. Clin. Exp. Immunol. 118 (1999) 392-401
13. Vieira P.L., de Jong E.C., Wierenga E.A., Kapsenberg M.L., and Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J. Immunol. 164 (2000) 4507-4512
14. Rissoan M.C., Soumelis V., Kadowaki N., Grouard G., Briere F., de Waal Malefyt R., and Liu Y.L. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283 (1999) 1183-1186
15. Siegal F.P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P.A., Shah K., Ho S., Antonenko S., and Liu Y.L. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (1999) 1835-1837
16. Kadowaki N., Antonenko S., Lau J.Y., and Liu Y.J. Natural interferon α/β-producing cells link innate and adaptive immunity. J. Exp. Med. 192 (2000) 219-226
17. Brown R.D., Pope B., Murray A., Esdale W., Sze D.M., Gibson J., Ho P.J., Hart D., and Joshua D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 98 (2001) 2992-2998
18. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 4 (2004) 941-952
19. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., and Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 2 (1996) 1096-1103
20. Schultze J., Nadler L.M., and Gribben J.B. B7-mediated co-stimulation and the immune response. Blood Rev. 10 (1996) 111-127
21. Cella M., Scheidegger D., Palmer-Lehmann K., Lane P., Lanzavecchia A., and Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184 (1996) 747-752
22. Gabrilovich D.I., Ciernik I.F., and Carbone D. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts. Cell. Immunol. 170 (1996) 101-110
23. Hoffman T.K., Muller-Berghaus J., Ferris R.J., Johnson J.T., Storkus W.J., and Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res. 8 (2002) 1787-1793
24. Troy A.J., Summers K.L., Davidson K.P.J., Atkinson C.H., and Hart D.N. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. 4 (1998) 585-593
25. Almand B., Clark J.I., Nikitina E., van Beyne J., English N.R., Knigh S.C., Carbone D.P., and Gabrilovich D.I. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166 (2001) 678-689
26. Della Bella S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., Clerici M., Greco M., and Villa M.L. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 89 (2003) 463-1472
27. Troy A., Davidson P., Atkinson C., and Hart D. Phenotypic characteristics of dendritic cell infiltrate in prostate cancer. J. Urol. 160 (1998) 214-219
28. Steinbrink K., Graulich E., Kubsch S., Knop J., and Enk A. CD4+ and CD8+ anergic T cells induced by interleukin-10-treated human dendritic cells display antigen specific suppressor activity. Blood 99 (2002) 2468-2476
29. Whiteside T. Immune suppression in cancer: effects on immune cells mechanisms and future therapeutic intervention. Semin. Cancer Biol. 16 (2006) 3-15
30. Kiertscher S.M., Luo J., Dubinett S.M., and Roth M.D. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J. Immunol. 164 (2000) 1269-1276
31. Portielje J.E., Gratama J.W., van Ojik H.H., Stoter G., and Kruit W.H. IL-12: a promising adjuvant for cancer vaccination. Cancer Immunol. Immunother. 53 (2003) 133-144
32. + T cell tolerance and linked suppression. J. Immunol. 163 (1999) 4805-4810
33. Pinzon-Charry A., Schmidt C.W., and Lopez J.A. The key role of CD40 ligand in overcoming tumor-induced dendritic cell dysfunction. Breast Cancer Res. 8 (2004) 402
34. Alldawi L., Takahashi M., Narita M., Ayres F., Tsukada N., Osman Y., Furukawa T., and Aizawa Y. Effect of prostaglandin E2 lipopolysaccharide IFN-gamma and cytokines on the generation and function of fast-DC. Cytotherapy 7 (2005) 195-202